Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TGTX
TG THERAPEUTICS, INC.
NASDAQ
$53.93
▼ DOWN 3.21% (-1.79)

KEY STATISTICS

Market Cap$8.26 B
52w High$59.30
52w Low$26.76
Dividend Yield—
Frequency—
P/E19.54
Volume1.03M
Shares Out.153.08M

COMPANY

LEADERSHIP

Michael S. Weiss
CHIEF EXECUTIVE
Michael S. Weiss

COMPENSATION 2026

Salary$875,000
Stock Awards$23,550,000
Incentive Plan Pay$1,146,250
All Other Comp.$0
Total$25,571,250

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 3, 2010
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
399

PRICE TARGET

Target High$83.00
Target Low$78.00
Target Median$80.50
Target Consensus$80.50

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$247.06M
NOV
2
MON

SPLIT RECORD

DATETYPERATIO
2012-04-30Reverse4:225
2011-07-19Reverse1:50
2011-07-14Reverse1:50
2003-09-29Reverse1:5

PRICE

$53.93 ▼ DOWN 3.21% (−$1.79)
OVERLAYS
$54.00$54.50$55.00$55.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM53.93

About TG Therapeutics, Inc.

https://www.tgtherapeutics.com ↗

TG Therapeutics, Inc. is a biopharma company developing novel treatments for B-cell cancers and autoimmune diseases, with products like Ublituximab, Umbralisib, and Cosibelimab.

INDUSTRY

Biotechnology

A PRODUCT TG THERAPEUTICS, INC. IS KNOWN FOR

BRIUMVI® (ublituximab-xiiy)
BRIUMVI® (ublituximab-xiiy)

BRIUMVI is an FDA-approved monoclonal antibody for treating relapsing multiple sclerosis in adults, serving as the company's primary commercial product and a major revenue source.

COMPETITORS

COMPETITOR
BIIB COMPARE
BMY COMPARE
JNJ COMPARE
NVS COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$159.32M $189.11M ▲$201.31M ▲$235.79M ▲
Royalty— $5.01M — —
License Revenue$2.39M $0 ▼$3.61M ▲$4.54M ▲
Other Revenue— $3.03M — —

Revenue by Geography

MapREGIONQ3-2025Q1-2026Q2-2026
UNITED STATES$152.9M $194.8M ▲$227.7M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
211
LISTED HERE
26
RANKED BY POSITION SIZE
XUU.TO
0.01% · 8.0M
VTS.AX
0.01% · 4.4M
XBI
1.06% · 2.3M
FBT
2.95% · 1.6M
SCHA
0.15% · 625.1K
PSC
0.56% · 281.2K
DFAS
0.08% · 218.6K
FESM
0.14% · 167.5K
XRS2.DE
0.26% · 133.0K
PSCH
3.69% · 123.6K
LABU
0.72% · 82.6K
RSSL
0.25% · 69.5K
BBMC
0.17% · 64.9K
EZM
0.34% · 59.2K
GSSC
0.25% · 49.6K
FFTY
3.47% · 48.1K
JHSC
0.33% · 43.5K
FSML
1.28% · 34.8K
JSML
0.46% · 31.7K
BBP
1.38% · 29.6K
SIXL
0.78% · 28.8K
BKMC
0.20% · 24.3K
PINK
0.32% · 22.4K
TPSC
0.26% · 18.5K
ETLZ.DE
0.38% · 15.2K
HY
HYP
1.09% · 14.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
47.98%
HOLDERS
538
TOP 12 OF 538 · RANKED BY POSITION SIZE
Blackrock, Inc.
22.3M sh · $739.24M
Vanguard Group Inc
15.8M sh · $472.22M
State Street Corp
8.6M sh · $287.35M
Soleus Capital Management, L.P.
4.0M sh · $133.85M
Geode Capital Management, LLC
3.6M sh · $200.14M
Clearbridge Investments, LLC
3.4M sh · $102.79M
D. E. Shaw & Co., Inc.
3.4M sh · $186.84M
Price T Rowe Associates Inc /Md/
2.8M sh · $152.06M
Congress Asset Management Co /Ma
2.6M sh · $142.85M
Two Sigma Investments, LP
2.5M sh · $135.65M
Goldman Sachs Group Inc
2.3M sh · $127.15M
Jane Street Group, LLC
2.0M sh · $67.82M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings2
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Sale (Partial)
2020-09-08

INSIDER TRADES

★
DIRECTOR
Charney Laurence N
Sale · 5.1K shares
2026-08-06
★
DIRECTOR
Charney Laurence N
Sale · 500 shares
2026-08-07
★
DIRECTOR
Charney Laurence N
Sale · 450 shares
2026-08-07
★
DIRECTOR
Lonial Sagar
Purchase · 8.3K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 1
UNDERPERFORM 1
NEUTRAL 1
5 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT B. Riley Securities BUY HC Wainwright & Co. BUY B of A Securities UNDERPERFORM Goldman Sachs NEUTRAL

SECTORS PEERS

PEERPRICE
ARWR$84.91COMPARE
KRYS$351.46COMPARE
KYMR$118.15COMPARE
PTGX$144.33COMPARE
PCVX$59.84COMPARE
IMVT$41.20COMPARE
ALKS$47.41COMPARE
PTCT$70.09COMPARE